Drugs / Anti-FLT3 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06786533 | Jan 2025 → Jan 2027 expected | acute myeloid leukemia | Hemogenyx Pharmaceuticals LLC | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-FLT3 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06786533 ↗ |
| Modality | Cell therapy | “anti-FLT3 CAR-T” NCT06786533 ↗ |
| Target | FLT3 | “Anti-FLT3 CAR-T cells” NCT06786533 ↗ |